Trial Profile
Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PACAMUS
- 03 Apr 2022 Status changed from discontinued to completed.
- 02 Nov 2020 Status changed from recruiting to discontinued.
- 13 Feb 2013 New source identified and integrated (German Clinical Trials; DRKS00004368).